Last week, Dennis Crouch highlighted recent decisions from the Patent Office Board of Appeals and Interferences that evaluated the patent-eligibility of claims under 35 USC § 101. One case with relevance to biotech and pharmaceutical applicants upheld the § 101 rejection of IBM claims directed to methods for clustering genes having potential functional similarity by comparing gene expression profiles based on both the time and intensity of gene expression. In that case, In re Kelkar, the Board found that the claims failed the “machine or transformation test” (MOT) and were directed to an abstract idea, despite language that invoked the use of a computer.
Category Archives: USPTO Board Decisions
Subscribe to this Blog
Topics
- 101
- 102
- 103
- Bilski
- Biosimilars
- Claim Construction
- District Court Decisions
- Doctrine of Equivalents
- Duty of Disclosure
- Federal Circuit Decisions
- Inequitable Conduct
- Infringement
- International Patent Practice
- Life Sciences Agreements
- Patent Office Practice
- Patent Reform
- Patent Term Adjustment
- Patent Term Extension
- Personalized Medicine
- Prometheus
- Reasonable Royalty
- Reexam
- Supreme Court Decisions
- Uncategorized
- USPTO Board Decisions
- USPTO Proposed Rule Changes
- Written Description
Recent Updates
- In Re Montgomery: Inherently Therapeutic
- Federal Circuit Upholds Declaratory Judgment Jurisdiction Over Subsequent ANDA Litigation
- USPTO Announces QPIDS Pilot Program For Post-Issue Fee Information Disclosure Statements
- Should “Economically Significant” Inventions Be Subject To Secrecy Orders?
- Public Comments Criticize USPTO’s Proposed Rules For “Routine Discovery,” “Patentee Estoppel,” and Amendments in Board Trial Proceedings
Twitter Updates
@PharmaPatents PharmaPatents' Recent Twitter Posts
The connection to twitter has returned an error. Please try again later.Follow on Twitter